Clinical trials: Sea Sickness
Motion Sickness, Space, Motion Sickness
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
The primary specific aim is to evaluate the use of intranasal scopolamine gel and sensory augmentation as an integrated countermeasure to mitigate motion sickness and enhance sensorimotor performance.
- Conditions
- Motion Sickness, Space, Motion Sickness, Sea Sickness
- Trial name
- NCT05886660
- Testing
- DPI-386 Nasal Gel
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Repurposed Therapeutics, Inc.